About 10 percent more students graduated medical school debt-free in 2016 than in 2010, despite lower scholarship funding, suggesting a higher concentration of students from wealthy backgrounds.

The public health crisis in the wake of Hurricane Harvey will play out over days, months and years. For a case study in how to best handle such a massive challenge, a recent article by the American Heart Association looks back to 2004 and the destruction of New Orleans by Hurricane Katrina.

A noninvasive technology used to diagnose and treat individuals with suspected coronary artery disease (CAD) is now available to patients covered by Anthem Blue Cross Blue Shield, Blue Shield of California and Blue Cross and Blue Shield of Alabama.

DANVERS, Mass., Aug. 28, 2017 — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has accepted the resignation of its Chief Financial Officer, Michael Tomsicek, effective August 24, 2017. After two years, Mr. Tomsicek is leaving the Company to pursue other interests.

Researchers at the European Society of Cardiology Congress are urging a rethink of global dietary guidelines in light of new data.

A widely accepted model systematically underpredicts major atherosclerotic cardiovascular disease (ASCVD) risk in disadvantaged communities, according to a new study in Annals of Internal Medicine.

Unless you were lucky enough to be on an extended summer vacation, you know that CMS proposed to halt bundled payment programs for Episode Payment Models (EPMs) for MI and bypass surgery and the Cardiac Rehabilitation Incentive (CRI) payment model. (Public comment on the changes can be made through October 16th.)

The wholesale list price of evolocumab would need to be slashed by roughly one-third—from $14,253 to $9,669—for the cholesterol-lowering drug to meet generally accepted cost-effectiveness standards for treating patients with atherosclerotic cardiovascular disease (ASCVD), according to new research.